Mark Mendel is managing director at Mendel Consulting LLC, consulting on venture fund management, company formation, and emerging company development in the biopharmaceutical and medical device sectors. He also supports company-building and fundraising for Flow Forward Medical and Metactive Medical, medical device spin-outs of Novita Therapeutics.
Previously, Mark was venture partner at NoVita Therapeutics, and before that, Director, Invention Development at Intellectual Ventures. Prior to joining Intellectual Ventures, Mark served as a consultant and helped to nurture multiple biotech and medical device companies through their seed stage, including Proteon Therapeutics and ValveXchange, where he served at startup CEO.
Mark served as managing director of RiverVest Venture Partners, which he co-founded. While at RiverVest, he served as founding CEO and later Chairman of the Board of Auxeris Therapeutics. He also led investments in and served as a member of the board of CyDex (acquired by Ligand Pharma) and as a board observer at Conforma Therapeutics (acquired by Biogen-Idec), CGI Pharmaceuticals (acquired by Gilead) and Xcyte Therapeutics (acquired by Cyclacel Pharmaceuticals). Before RiverVest, Mark was a vice president with ARCH Venture Partners. During his four-year tenure there, he established the firm's New York City operations, co-led the seed financing at Optobionics and served as board observer at Optobionics and GenVec.
Mark worked in medical research at the Scheie Eye Institute and at Massachusetts General Hospital, in product development at ALYX Medical, and in manufacturing at Polaroid.
Education, Personal, and Fellowship
Mark earned his BS in mechanical engineering at Cornell University and received his MSE and PhD in bioengineering from the University of Pennsylvania, where he was awarded full funding through NIH pre-doctoral fellowships. He also took graduate courses in organic chemistry at Harvard University. Mark serves on the advisory board of Cornell Outdoor Education.
Mark Mendel is a member of the Charter Class of Fellows and served his fellowship under mentor Steve Lazarus at ARCH Venture Partners in New York. He served as mentor to Class 8 member Scott Naisbitt at RiverVest Venture Partners.